Market Analysis insights.
Therapeutic area deep-dives and market landscape reports
CDMO Market Analysis 2026: Size, Trends & Key Players
Comprehensive CDMO market analysis covering market size, key players, selection criteria, and outsourcing trends.
Gene Therapy Market 2026: Approved Products, Pipeline & Licensing Deals
Zolgensma ($1.24B), Elevidys ($820M+), and CRISPR-based Casgevy are transforming rare disease. Track AAV, CRISPR, and in vivo gene therapy licensing opportunities.
Orphan Drug Designation & Rare Disease Licensing 2026: Market & Strategy Guide
The $217B orphan drug market covers only 5% of rare diseases. 7-year exclusivity, premium pricing, and BioMarin's $4.8B Amicus deal signal massive BD opportunity.
ADC Market 2026: Antibody-Drug Conjugate Pipeline, Deals & Licensing
15 FDA-approved ADCs, $13.5B market, and Enhertu leading at $3.75B. Analysis of platform deals, China-origin assets, and licensing strategy for BD executives.
CAR-T Cell Therapy Market 2026: Products, Pipeline & Licensing Opportunities
The CAR-T market surpassed $5B with CARVYKTI growing 93% YoY. Allogeneic platforms, autoimmune expansion, and Lilly's $2.4B Orna deal reshape the landscape.
Biosimilars & Patent Cliff Licensing 2026: $100B+ Revenue at Risk
Humira, Stelara, Keytruda — the biggest patent cliffs in pharma history are creating a $39.6B biosimilar market. Licensing guide for BD executives.
PD-1/VEGF Bispecific Antibody Landscape 2026: Pipeline, Deals & Licensing
Ivonescimab's $5B Summit deal, HARMONi-2 data beating Keytruda, and 9+ pipeline candidates. The hottest bispecific antibody space in oncology.
GLP-1 Licensing Landscape 2026: The Hottest Deal Space in Pharma
$50 billion in deal value. 8+ mega-deals. The race for next-gen oral, monthly, and combination obesity treatments.
The Vision Lifesciences brief.
One email per month. New essays and deal-flow notes from the partner team. Unsubscribe anytime.